LA JOLLA, Calif., March 25, 2021 /PRNewswire/ -- Avidity
Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company
pioneering a new class of oligonucleotide-based therapies called
Antibody Oligonucleotide Conjugates (AOCs™), today
announced that management will be participating in the following
virtual investor conferences:
- Guggenheim Healthcare Talks—Genomic Medicines and Rare
Disease Day Conference
Thursday,
April 1st, 2021, 6:00 am
PDT
-
- Panel on Duchenne Muscular Dystrophy (DMD)
- Participants include:
-
- Arthur Levin, PhD, Chief
Scientific Officer, Avidity Biosciences
- Michael Binks, MD, Vice
President of Clinical Research, Pfizer
- Louise Rodino-Klapac, PhD, Chief
Scientific Officer, Sarepta
Therapeutics
- Carl Morris, PhD, Chief
Scientific Officer, Solid Biosciences
- Sam Wadsworth, Chief Scientific
Officer, Ultragenyx Pharmaceutical
- 2021 Virtual Wells Fargo Biotech Corporate Access
Day
Tuesday, April
6th, 2021
-
- Avidity management participation in investor 1x1 meetings
- 20th Annual Needham Virtual Healthcare
Conference
Monday, April
12th, 2021, 12:45pm
PDT
-
Live webcasts of the Guggenheim panel and Needham presentation
will be available on the Investors section of Avidity's
website and a replay of both events archived on the site.
About Avidity
Avidity Biosciences, Inc. is driven to
change lives with a new class of therapies called Antibody
Oligonucleotide Conjugates (AOCs) that are designed to overcome
current limitations of oligonucleotide therapies in order to treat
a wide range of serious diseases. Avidity's proprietary AOC
platform combines the tissue selectivity of monoclonal antibodies
and the precision of oligonucleotide therapies to access previously
undruggable tissue and cell types and more effectively target
underlying genetic drivers of diseases. Avidity's lead product
candidate, AOC 1001, is designed to treat myotonic dystrophy type
1, and its other muscle programs are focused on the treatment of
Duchenne muscular dystrophy, facioscapulohumeral muscular
dystrophy, Pompe disease and muscle atrophy. In addition to its
muscle franchise, Avidity has research efforts focused on immune,
cardiac and other cell types.
Avidity is headquartered in La Jolla, CA. For more
information about Avidity's science, pipeline and people,
please visit www.aviditybiosciences.com and engage with
Avidity on LinkedIn.
Contacts:
Company:
Mike MacLean
(858) 401-7900
mikemaclean@aviditybio.com
Media and Investors:
Amy Conrad
Juniper Point
(858) 366-3243
amy@juniper-point.com
View original
content:http://www.prnewswire.com/news-releases/avidity-biosciences-to-participate-in-upcoming-investor-conferences-301256325.html
SOURCE Avidity Biosciences, Inc.